User: Guest  Login
Title:

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Document type:
Journal Article; Journal Article
Author(s):
Pfreundschuh, Michael; Poeschel, Viola; Zeynalova, Samira; Hänel, Mathias; Held, Gerhard; Schmitz, Norbert; Viardot, Andreas; Dreyling, Martin H; Hallek, Michael; Mueller, Carsten; Wiesen, Martin H J; Witzens-Harig, Mathias; Truemper, Lorenz; Keller, Ulrich; Rixecker, Tanja; Zwick, Carsten; Murawski, Niels
Abstract:
To study pharmacokinetics, toxicity, and efficacy of prolonged rituximab exposure in elderly patients with diffuse large B-cell lymphoma (DLBCL).In the SMARTE-R-CHOP-14 trial, rituximab 375 mg/m(2) was administered, together with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone on a 14-day schedule (6×R-CHOP-14), on days -4, 0, 10, 29, 57, 99, 155, and 239. Pharmacokinetics and outcome were to be compared with those of patients who had received 6×R-CHOP-14...     »
Journal title abbreviation:
J Clin Oncol
Year:
2014
Journal volume:
32
Journal issue:
36
Pages contribution:
4127-33
Language:
eng
Fulltext / DOI:
doi:10.1200/JCO.2013.54.6861
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/25403207
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX